Dr. Kehan Xu is an adjunct professor at City University of Hong Kong. Dr. Xu’s research focuses on the marketing-finance interface, marketing intervention effectiveness, entrepreneurship, and portfolio strategies of innovative industries (e.g., quantitative long/short, event-driven). Dr. Xu has published in leading scholarly journals, such as Journal of the Academy of Marketing Science, Journal of Management Accounting Research, Journal of Management, and Academy of Management Perspectives. Dr. Xu has also presented research findings based on quantitative models to the American Marketing Association Annual Conference on the topics of product innovation, brand asset disposal and acquisition, and short-selling. Dr. Xu received his PhD in strategy from the Mays Business School at Texas A&M University and his MBA in investments from the University of Miami. Dr. Xu is the co-founder of AD BioPharma, which focuses on innovative monoclonal antibody (mAb) drugs of cardiovascular diseases and tumors. He served as the CFO and executive director for Dawnrays Pharmaceutical (Holdings) Limited, a company listed on the Hong Kong Stock Exchange, before starting his PhD. 

Journal Publications and Reviews